Treatment of ventricular tachycardia: consider ablation sooner by Bloom, Heather L
Treatment of ventricular tachycardia: consider ablation sooner
Heather L Bloom
Address: Division of Cardiovascular Medicine, Emory University School of Medicine and Atlanta VA Medical Center,
1670 Clairmont Rd, Decatur, GA 30033, USA
Email: hbloom@emory.edu
F1000 Medicine Reports 2009, 1:71 (doi:10.3410/M1-71)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/71
Abstract
Ventricular tachycardia (VT) is a leading cause of morbidity and mortality for many patients, with a
significant emotional and economic burden caused by implantable cardioverter-defibrillator (ICD)
shocks and the requirement of medication with significant side effects. Additionally, 10% of VT occurs
in patients with no structural heart disease. Until quite recently, ablation for VT has been reserved as
the procedure of last hope for those who have ongoing recurrences despite maximal medical therapy
and who are traumatized by multiple ICD shocks [1]. However, recent advances in imaging
technology and three-dimensional intracardiac mapping systems have significantly improved the safety
and efficacy of VT ablation procedures. Thus, ablation for VT should no longer be reserved as a last-
resort bailout procedure and should move into the realm of routine electrophysiology treatment.
Introduction and context
Clinical management of ventricular arrhythmias (VAs) is
problematic and often complicated by the need for
rapid diagnosis and treatment. Monomorphic ventricular
tachycardia (VT) is most commonly due to re-entry and
is commonly seen in patients with underlying structural
heart disease. There is typically a zone of slow conduc-
tion due to scarring or inhomogeneous myocardium.
Causes include prior infarct, primary cardiomyopathy,
surgical scarring, hypertrophy, and muscle degeneration.
Underlying pathologies include sarcoid, Chagas disease,
dilated cardiomyopathy, valvular heart disease, or
arrhythmogenic right ventricular dysplasia [1-5]. Stan-
dard treatment of VAs due to these pathologies has
been beta-blockers, anti-arrhythmic drugs, and implan-
tation of implantable cardioverter-defibrillators (ICDs).
Beta-blockers are the only medication with proven
efficacy in reducing sudden cardiac death, although
anti-arrhythmics may be effective as an adjunctive
therapy to reduce VA burden and prevent ICD therapies
[6]. Historically, mapping VTs in the electrophysiology
(EP) lab for ablation in cardiomyopathic patients has
been problematic due to hemodynamic instability.
Advances in imaging and three-dimensional (3D)
mapping systems, leading to improved substrate defini-
tion, have allowed significant improvements in these
procedures for these patients.
Additionally, 10% of monomorphic VT occurs in
patients with structurally normal hearts [7]. Mechan-
istically, these VTs are more often due to triggered activity
or abnormal automaticity. Although patients with
idiopathic VTs usually have a good prognosis, sudden
death is still known to occur and pharmacological
treatments have poor efficacy and high rates of side
effects.Most, if not all, of these atypical VTs are amenable
to ablation, which has been considered first-line therapy
for these patients [6]. Recent advances in technology and
techniques, and new data supporting the safety and
efficacy of palliation in numerous disease states, support
performing ablation more routinely in patients with
structural heart disease.
Ablation of ventricular tachycardia: historical perspective
Historically, electrophysiologists had only the tools of
pace-mapping, entrainment, and activation mapping to
attempt ablation of VT. Pace-mapping refers to assessing
the activation sequence of the VT by 12-lead
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where the paced QRS morphology matches the clinical
VT pattern is likely to be the site of origin for a focal VT,
or the exit site for scar-related VT. Activation mapping
refers to the method of moving an electrode catheter
point by point through multiple ventricular sites during
VT and recording the electrogram at each site. The site of
earliest activation (that is, the earliest onset of electrical
depolarization) identifies the origin of the tachycardia,
or exit site. Entrainment mapping is used for re-entry
circuits and consists of pacing during VT at a rate faster
than the tachycardia, from a site thought to be within the
circuit. Examining the change in QRS morphology
during pacing and the post-pacing timing of resumption
of the VT helps determine whether the paced site is
within the re-entry circuit. Both activation and entrain-
ment mapping require a hemodynamically stable
arrhythmia to allow these manipulations. All three
techniques are tedious and time-consuming. Another
confounding problem is that multiple morphologies of
VT often can be induced, leading to uncertainty as to
which is the clinical arrhythmia.
Recent advances
Advances in ablation technique
Within the last decade, attention has turned to substrate
mapping. Substrate mapping uses our understanding of
the pathophysiology of re-entrant arrhythmias to char-
acterize areas in the myocardium likely to sustain
re-entry based on anatomic features or electrophysiolo-
gical characteristics (for example, a scar can be identified
by bipolar electrogram amplitude). Electroanatomic
mapping systems create a 3D computer-generated
image of the ventricular geometry. These are either
contact or non-contact systems that consist of electro-
magnetic fields that record intracardiac electrical activa-
tion points from catheter electrodes. They display a map
of the anatomy with the intracardiac catheters super-
imposed, and this map can reduce fluoroscopic radiation
exposure. They also can produce voltage maps of the
myocardium which define areas of ventricular scar based
on absolute voltage. Substrate-based mapping allows
ablation lines to be drawn from areas of scar to
electrically inactive areas to cut off potential re-entrant




Magnetic resonance imaging (MRI) identifies non-viable
myocardium, focal fibrosis, and peri-infarct zone volume
via late gadolinium enhancement. In multiple disease
processes, this non-viable myocardium has proven to
be predictive of VT prevalence or mortality or both. MRI-
defined border zone function has been demonstrated to
correlatewithinducibility ofVT [8]. MRI clearlydelineates
the location of scar tissue, which often corresponds to
critical areas within VT circuits. This detailed anatomic
knowledge allows pre-procedure planning of ablation
strategy, suggesting how lines can be drawn to link non-
viable myocardium with electrically neutral structures
such as valves. Software also allows incorporation of the
MRI image into the electroanatomic map in the lab for
real-time image correlation with substrate. Unfortunately,
MRI cannot be performed in patients with pacemakers or
ICDs, limiting its utility immensely [9,10].
Positron emission tomography - computed tomography
Ablation of scar-related VT is facilitated by accurate
definition of the scar borders. Positron emission
tomography (PET) imaging is extremely accurate in
defining 3D scar anatomy. Two recent studies demon-
to the voltage electroanatomic map. Thus, simultaneous
display of the PET-CT scar and border zone information
can be incorporated into the in-lab voltage map. This
improves accuracy of the in-lab map and allows
simultaneous visualization of the anatomic image plus
substrate to facilitate identification of critical areas to
target for VT ablation [11,12].
Recent data on ablation efficacy and safety
in multiple disease processes
Ablation of ventricular tachycardia in patients with ischemic and
non-ischemic cardiomyopathy
The SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) investigators reviewed their patients who received
primary prevention ICDs. Patients who had VT had a
significant increase in the risk of death compared with
those who did not experience VT (hazard ratio 5.7,
P < 0.001) [13]. A study published in The New England
Journal of Medicine in December 2007 randomly assigned
patients with coronary artery disease and sustained VTs
undergoing ICD implantation to substrate-based cathe-
ter ablation versus non-invasive interventions (medi-
cation) [14]. Patients on the ablation arm had less ICD
therapy for VA (hazard ratio 0.35, P = 0.007) and a non-
significant trend toward lower mortality (9% versus
17%, P = 0.29) [14]. There were no deaths from the
ablation procedure or evidence of adverse events. These
data support the contention that catheter ablation is
useful as a palliative therapy for malignant VAs in
patients with primary prevention ICDs, and suggest that
further investigation may reveal improvements in
mortality after VT ablation. The University of Michigan
recently reviewed their experience with mapping and
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strated that PET - computed tomography (CT) scans
the 3D mapping system in the EP lab and registered
performed pre-procedure can also be integrated intoablation for 35 non-ischemic VT patients ablated in
2007. Patients who failed endocardial ablation under-
went a second procedure with transcutaneous epicardial
mapping and ablation. The authors report a 60-70%
success rate in controlling VTs refractory to medical
management and a major complication rate of less than
5% [15]. Carbucicchio and colleagues [16] have demon-
strated improved mortality outcomes when VT ablation
is offered to extremely sick patients in VT storm. The
authors prospectively evaluated 95 patients with cardi-
omyopathy and electrical storm. At the 22-month
follow-up, 92% were free of electrical storm and 66%
were free of VT recurrence [16]. Stevenson and colleagues
[17] evaluated 231 patients with ischemic cardiomyo-
pathy and recurrent VT. Ablation was carried out in all
patients with an electroanatomic mapping system to
assist substrate mapping during sinus rhythm. At the
6-month follow-up, 53% of patients were free of VT, and
the 6-month frequency of VT episodes was reduced from
a median of 11.5 to 0 in the 142 patients who had ICDs.
A total of seven deaths were recorded within 7 days of the
procedure, and the 1-year mortality rate was 18% [17].
Ventricular tachycardia ablation in cardiac sarcoid
In a multicenter registry, 42 patients with a diagnosis of
cardiac sarcoidosis were identified and followed. When
VT occurred, the patients first received ICD placement,
immunosuppressive agents, anti-arrhythmic medications,
and then radio frequency (RF) ablation. Nine patients
were brought for ablation procedures and a total of
44 VTs were induced. Endocardial RF ablation was
performed in eight patients, and epicardial RF ablation
was performed in one patient. Elimination was successful
in 31 of 44 (70%) VTs, resulting in a decrease from 271 to
4 episodes of VT. All patients had either a decrease or a
complete elimination of VT during a mean follow-up of
19.8 months. The authors conclude that catheter ablation
of VT in sarcoid patients can significantly reduce VT
burden [18].
New anatomic sites
Catheter ablation in the sinus of Valsalva
VAs can come from the endocardium or the epicardium.
Epicardial arrhythmias arising from the aortic valve and
the aortic sinus of Valsalva have been described by
several groups. Rillig and colleagues [19] examined a
group of 15 patients who underwent ablation in the
aortic sinus of Valsalva for VT or premature ventricular
contractions (PVCs). The authors reported success in
13 of 15, with recurrence and success in a second
ablation procedure in the other 2 patients. There were no
major complications, leading the authors to conclude
that ablation within the sinus of Valsalva is a safe and
effective approach for VT/PVCs [19].
Epicardial ablation
For both ischemic and non-ischemic cardiomyopathy,
up to one-third of VT circuits are inaccessible from the
endocardium. Percutaneous pericardial access allows for
many of these VTs to be ablated from the epicardial
service. This requires percutaneous access to the peri-
cardium in the subxyphoid region. Although this
procedure does carry risks of injury to epicardial coronary
arteries, the phrenic nerve, subdiaphragmatic vessels,
and the right ventricle, experienced centers are finding
the procedure to be safe and well tolerated. Grimard
and colleagues [20] last month published a review of
35 epicardial procedures attempted in 32 patients. The
authors obtained an immediate successful ablation of the
clinicalVTin22of29(76%)cases.Duringameanfollow-
up of 384 ± 405 days, 9 patients (26%) experienced a
recurrence of a sustained VT. One patient died from
tamponade during the procedure. The authors concluded
that the safety and efficacy were similar to those of
endocardial ablation procedures [20].
Implications for clinical practice
The presence of VAs clearly increases risk of mortality and
is a significant cause of morbidity. VT episodes can be
terminated, but not prevented, using an ICD. In patients
with these devices, anti-arrhythmic drug therapy is often
administered to prevent VT; however, these agents have
adverse effects and relatively poor efficacy. Patients who
receive ICD shocks have significant impairment of
quality of life. Although the ability to permanently
eliminate VT is determined by the substrate, recent
evidence shows significant benefits in many patients,
regardless of the underlying pathology. Improvements
in technologies to assist with VT ablation, including
improved imaging systems, 3D electroanatomic map-
ping systems that allow for substrate mapping in
hemodynamically compromised patients, and integra-
tion of pre- and peri-procedure images, have vastly
improved the safety and efficacy of these techniques.
New ablation sites, including the epicardium, also show
great promise for future improvements in efficacy. Many
centers have provided data on the safety and efficacy of
VT ablation for a variety of pathological conditions.
Thus, ablation of VT should be moved out of the realm
of a treatment of last resort and should be considered
sooner. We have demonstrated that we have the
technology not only to palliate the sickest patients, but
to improve, and potentially even save, many lives.
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